<DOC>
	<DOCNO>NCT01969643</DOCNO>
	<brief_summary>This study examine safety tolerability SGN-LIV1A patient metastatic breast cancer . Increasing dose SGN-LIV1A give every 3 week alone combination trastuzumab .</brief_summary>
	<brief_title>A Safety Study SGN-LIV1A Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Pathologically confirm diagnosis breast cancer radiographic evidence incurable , unresectable , locally advanced metastatic disease ( LA/MBC ) One following : ) Triplenegative disease ( ER/PR/HER2negative ) receive least 2 prior cytotoxic regimen incurable , unresectable , LA/MBC setting ; b ) ER and/or PRpositive/HER2negative disease receive least 2 prior cytotoxic regimen incurable , unresectable , LA/MBC set longer candidate hormonal therapy ; c ) Combination Arm : HER2positive disease receive least 2 prior cytotoxic regimen incurable , unresectable , LA/MBC set . Positive LIV1 expression central pathology review archival newly obtain tumor tissue biopsy Measurable disease Eastern Cooperative Oncology Group performance status 0 1 Combination Arm : adequate heart function Preexisting neuropathy Grade 2 high Malignant CNS disease definitively treat Pgp inducers/inhibitors strong CYP3A inducers/inhibitors within 2 week first dose Combination Arm : hypersensitivity trastuzumab</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Antibody-drug conjugate</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>Metastatic</keyword>
	<keyword>LIV-1 protein , human</keyword>
	<keyword>Trastuzumab</keyword>
</DOC>